Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia

Abstract Background The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood. The purpose of this study was to assess how nirmatrelvir/ritonavir treatment affected both PCC and health-related quality of...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ee Vien Low, Mohan Dass Pathmanathan, Yi Yang Ten, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2024-08-01
Edice:	BMC Infectious Diseases
Témata:	Nirmatrelvir/ritonavir post-COVID condition Long COVID Malaysia
On-line přístup:	https://doi.org/10.1186/s12879-024-09679-1
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!